arrow
V

Vildan Özkocaman

department of internal medicine
H指数:18
被引数:1,217

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Defining a critical therapeutic window: cyclosporine exposure in months 1–2 as a determinant of acute graft-versus-host disease in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplantation from matched related donors

定义一个关键的治疗窗口:环孢素暴露在1-2个月作为匹配相关供者异基因造血干细胞移植急性白血病患者的急性移植物抗宿主病的决定因素

2026-06-150
OAAI
Clinical outcomes and prognostic factors in hematologic malignancy patients with probable CMV pneumonia

血液恶性肿瘤患者中可能发生CMV肺炎的临床结局及预后因素

2026-06-030
OA
Comparative Evaluation of Single-Dose and Split-Dose Melphalan Conditioning Concerning Toxicity Profiles and Engraftment Kinetics: A Propensity Score-Matched Analysis

单剂量与分次剂量美法仑预处理方案的毒性谱和植入动力学比较评估:一项倾向性评分匹配分析

2026-05-300
PRE
Management of Rituximab-Associated Hypersensitivity Reactions with Successfully Applied Desensitization Protocols: A Clinical Experience of 46 Infusions in 11 Patients

利妥昔单抗相关超敏反应的管理及成功应用减敏方案的临床经验:11例患者46次输注的案例报告

2026-05-280
OAAI
The Dynamic Endothelial Activation and Stress Index (EASIX) as a Predictor of Early Death and Long-Term Survival in Acute Promyelocytic Leukemia (APL): A Multicenter Study

动态内皮激活和应激指数(EASIX)作为急性早幼粒细胞白血病(APL)早期死亡和长期生存的预测指标:一项多中心研究

Cancers
IF4.4
2026-03-050
OAAI
Shifting Paradigms in Antifungal Prophylaxis and Their Effects on Candidemia Outcomes in Hematological Malignancies: A 14-Year Experience from a Single Tertiary Center

抗真菌预防策略的转变及其对血液系统恶性肿瘤患者念珠菌血症结局的影响:一家三级医疗中心14年的经验

2026-03-030
OAAI
Assessment of characteristics and treatment patterns of adult patients with acquired aplastic anemia in Turkiye (PLANE-TR)

评估土耳其成人获得性再生障碍性贫血患者特征及治疗模式的研究(PLANE-TR)

2026-02-200
OAAI
In-Hospital Mortality Among Hematological Malignancy Patients Undergoing Bronchoscopy for Suspected Invasive Pulmonary Aspergillosis: Focusing on Coinfections and Nodules on Chest CT

院内死亡率:在疑似侵袭性肺曲霉病的血液恶性肿瘤患者中接受支气管镜检查,重点关注胸片CT上的混合感染和结节

2025-09-290
PRE
Impact of posaconazole prophylaxis and antifungal treatment on BAL GM performance in hematology malignancy patients with febrile neutropenia: a real life experience
2023-11-012
PRE
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
2020-06-0716
PREAI